Page 25 - Vaccine

Expense on R&D for Covid-19 drugs, vax, devices will count as CSR

The CSR FAQs provide details of what would qualify as administrative overheads

Injecting certainty

India needs a coherent vaccination plan

Over 600 mn Covid-19 vaccine doses administered in India, says govt

India took 85 days to touch the figure of 100 million

Explained: What FDA full approval to Pfizer-BioNTech vaccine means

The research to develop a safe and effective Covid-19 vaccine was accelerated in 2020

Work on non-Covid vaccines gives pharma firms an injection of hope

Approach drug regulator, seeking permission to conduct clinical trials

Zydus to soon start work on developing a vaccine for Delta variant

Also plans trials for children aged three years and above. Its needle-free injection is to be assembled in India

Biden administration to start offering vaccine booster shots on Sept 20

The US will begin issuing more booster shots as soon as Sept. 20 to people who received their second shot at least eight months earlier

Serum Institute picks up 50% in glass vial maker Schott's Indian JV

Deal value not disclosed; former co-promoters Kaisha exits JV

Explained: What will it take to stop delta variant of coronavirus

Delta is both more infectious and more capable of evading immunity generated by either vaccination or a previous natural infection

Moderna, BioNTech lose nearly $60 billion in value in two-day drop

The declines deepened Wednesday with Moderna closing 16% lower and BioNTech dropping 14% as trading volume picked up

Decoded: Understanding the debate over coronavirus booster shots

US Centers for Disease Control and Prevention recommends that ad­ults receive boosters of the tetanus vaccine every dec­a­de

Covid-19 pandemic: Novavax shot may get nod in India even before US

SII and Novavax have now completed submission of all modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine

Covid-19 pandemic: Can Moderna buy its way into the $200 billion club?

The company disclosed during its earnings presentation Aug. 5 that it expects the shot to generate $20 billion in sales this year

Govt okays Bharat Biotech's Ankleshwar plant to produce Covaxin: Minister

Union minister Mansukh Mandaviya on Tuesday said the government has given approval to Bharat Biotech's Ankleshwar-based manufacturing plant to produce COVID-19 vaccine Covaxin. "Govt of India approves vaccine manufacturing facility for production of @BharatBiotech's #Covaxin in Ankleshwar, Gujarat," Mandaviya tweeted. The approval would help increase availability of COVID-19 vaccines in the country, he added. "Following PM @NarendraModi ji's vision of #SabkoVaccineMuftVaccine, this will increase vaccine availability & accelerate the world's largest vaccine drive," the minister who heads both Chemicals and Fertilisers and Health ministries noted. In May this year, Bharat Biotech had announced that it plans to produce an additional 200 million doses of Covaxin at its subsidiary's Ankleshwar-based facility. The Hyderabad-based firm had noted that it would utilise the manufacturing plant of its wholly-owned unit - Chiron Behring, to add another 200 million doses of Covaxin.

DRL seeks a booster from Sputnik V but hurdles in scaling up remain

Even as the company investigates complaints of malpractice in the Ukraine, hurdles in scaling up the Russian vaccine remain the bigger challenge in the near term

J&J seeks approval for single-dose Covid-19 vaccine in India

It is not clear whether J&J is seeking indemnity against adverse events following vaccination like its US peers

China pledges 2 billion Covid-19 vaccines globally through year's end

Xi Jinping pledged 2 billion doses of Chinese vaccines would be supplied to the world through this year, an increase that would add to country's efforts as the largest global exporter of vaccines

Novavax seeks OK for emergency use of Covid vaccine in India, Indonesia

Vaccine maker Novavax announced Thursday it has asked regulators in India, Indonesia and the Philippines to allow emergency use of its Covid-19 vaccine

Moderna Covid-19 vaccine tallies more than $4 billion in Q2 sales

Moderna's Covid-19 vaccine brought in more than $4 billion in second-quarter sales, helping to push the vaccine developer into a profit

Are coronavirus vaccines working? What the real world tells us

Delta, the strain first reported in India in October, is the most worrisome detected so far